Cognoa has gained regulatory recognition for its machine learning software as a class II diagnostic medical device for autism — meaning the digital health startup is now positioned to submit an application for full FDA clearance. Read More
Cognoa’s AI platform for autism diagnosis gets first FDA stamp
Reviewed by editorial staff
on
February 21, 2018
Rating: 5
No comments